DeltaRex-G shows survival gains in updated cancer data presented at ESMO
Updated clinical data on DeltaRex-G gene therapy showed response and survival benefits in advanced, chemoresistant sarcomas and other solid tumors, including ovarian cancer. The results were presented Oct. 23 at ESMO 2026 in Madrid and are slated for publication in Annals of Oncology.
Why it matters: - The updated dataset strengthens the case for DeltaRex-G in patients with late-stage solid tumors that have resisted standard treatment. - The findings add ovarian cancer to the therapy’s reported efficacy profile. - The study also points to a treatment approach that may work best when paired with FDA-approved drugs earlier in the disease course.
What happened: - The Sarcoma Oncology Center/Cancer Center of Southern California and the Aveni Foundation released updated results from the BLESSED Expanded Access program for DNG64-CAR-V, also called DeltaRex-G. - The data cover advanced pancreatic cancer, sarcoma, breast cancer and ovarian cancer under trial registration NCT04091295. - Investigators presented the results on Oct. 23, 2026 at the European Society for Medical Oncology 2026 Congress in Madrid. - The findings are set to appear in Annals of Oncology, the official journal of ESMO.
The details: - Tumor biomarker screening of 332 samples found enhanced CCNG1 expression in 100% of samples. - CCNG1 expression was high in 22% of samples, medium-high in 39%, medium-low in 35% and low in 4%. - Of the tested tumor samples, 88.6% were sarcomas, 2.7% were invasive ductal breast carcinoma, 0.9% were pancreatic ductal adenocarcinoma and 7.8% were other cancers, including serous ovarian adenocarcinoma. - Among evaluable patients, 5 of 10 had a partial response, for a 50% response rate. - One of those responses came from a patient treated first-line with DeltaRex-G plus FDA-approved drugs. - The overall clinical benefit rate was 90%, or 9 of 10 patients. - No treatment-related adverse events above grade 3 were reported. - Median progression-free survival was 6.7 months for sarcomas and 7.8 months across all cancer types. - Median overall survival was 18.7 months for sarcomas and 14.8 months across all pooled cancer types. - DeltaRex-G is an investigational tumor-targeted gene therapy vector designed to inhibit the CCNG1 proto-oncogene pathway and disrupt tumor growth and survival in hard-to-treat solid cancers. - The therapy was invented by Drs. Erlinda M. Gordon and Frederick L. Hall.
Between the lines: - The strongest signal in the update is not just response, but durability, with both progression-free and overall survival extending into ranges that are notable for chemoresistant stage 4 disease. - The biomarker data suggest DeltaRex-G may be most relevant in tumors with CCNG1 expression, which could matter for future patient selection. - Sant P. Chawla, who presented the data at ESMO, said the results build on prior survival gains and suggested first-line use with FDA-approved therapies could produce better outcomes for metastatic disease.
What's next: - The full dataset will be published in Annals of Oncology. - The broader implication is that future studies may further test DeltaRex-G in combination regimens and in biomarker-selected patients. - The Sarcoma Oncology Center and Aveni Foundation also point readers to their websites for more information and donations. More information
Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.
Sign up for:
The Madrid Wire
The daily local news briefing you can trust. Every day. Subscribe now.
Check Your Email!
We sent a one-time activation link to: .
Confirm it's you by clicking the email link.
If the email is not in your inbox, check spam or try again.
Welcome back!
is already signed up. Check your inbox for updates.